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Abstract In the present study, upon showing sexual dimor-
phism in dimethyl fumarate (DMF) efficacy to moderate the
clinical severity of experimental autoimmune encephalomy-
elitis (EAE) in Dark Agouti rats, cellular and molecular sub-
strate of this dimorphism was explored. In rats of both sexes,
DMF administration from the day of immunization attenuated
EAE severity, but this effect was more prominent in males
leading to loss of the sexual dimorphism observed in
vehicle-administered controls. Consistently, in male rats,
DMF was more efficient in diminishing the number of
CD4+ T lymphocytes infiltrating spinal cord (SC) and their
reactivation, the number of IL-17+ T lymphocytes and partic-
ularly cellularity of their highly pathogenic IFN-γ+GM-CSF+
IL-17+ subset. This was linked with changes in SC CD11b+
CD45+TCRαβ− microglia/proinflammatory monocyte prog-
eny, substantiated in a more prominent increase in the
frequency of anti-inflammatory phygocyting CD163+ cells
and the cells expressing high surface levels of immunoregu-
latory CD83 molecule (associated with apoptotic cells phago-
cytosis and implicated in downregulation of CD4+ T lympho-
cyte reactivation) among CD11b+CD45+TCRαβ– cells in
male rat SC. These changes were associated with greater in-
crease in the nuclear factor (erythroid-derived 2)-like 2 ex-
pression in male rats administered with DMF. In accordance
with the previous findings, DMF diminished reactive nitrogen
and oxygen species generation and consistently, SC level of
advanced oxidation protein products, to the greater extent in
male rats. Overall, our study indicates sex-specificity in the
sensitivity of DMF cellular and molecular targets and encour-
ages sex-based clinical research to define significance of sex
for action of therapeutic agents moderating autoimmune neu-
roinflammation-/oxidative stress-related nervous tissue
damage.
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Introduction
Multiple sclerosis (MS), the prototype of the autoimmune in-
flammatory disease of the central nervous system (CNS), is
characterized by breakdown of the blood-brain barrier, auto-
immune-mediated inflammation, and axonal damage [1,
2]. To date, the pathogenesis of MS has not been
completely understood. The biochemical analysis of cere-
brospinal fluid/blood samples and/or nervous tissue ho-
mogenates in MS [1, 3, 4] and experimental autoimmune
encephalomyelitis (EAE), the principal animal model of
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MS [5–7], implicated oxidative stress in pathogenesis of
EAE/MS. The damage of nervous tissue in EAE, as in
MS, is linked with reactive oxygen species (ROS) and
reactive nitrogen species (RNS) generation by mainly inflam-
matory monocyte progeny [8]. To corroborate the role of ROS
and RNS in pathogenesis of autoimmune-mediated diseases is
the beneficial effect of oxidative damage-reducing agents, as it
is dimethyl fumarate (DMF), on the clinicalMS [9–11], EAE in
mice [12], and experimental autoimmune neuritis in rats [13].
The beneficial effects of DMF on the neuroinflammation-
associated nervous tissue oxidative damage are ascribed to (i)
direct effects of this agent on oxidative stress, through suppres-
sion of pro-oxidative cascade and activation of endogenous
anti-oxidative defense system [9] and (ii) its indirect effects
related to limitation of inflammation cascade [12, 14–16].
Additionally, DMF is claimed to act as an anti-inflammatory
agent by activating the nuclear factor (erythroid-derived 2)-like
2 (Nrf2) pathway [9, 16, 17]. Namely, Nrf2 exerts twofold
effects. It activates transcription of genes encoding many anti-
oxidant defense enzymes, on one hand, and inhibits NF-κB-
mediated transcription of genes for proinflammatory mediators,
on the other hand [18]. To complicate this regulation, a recip-
rocal effect of NF-κB on Nrf2 function is also demonstrated
[19]. Moreover, it has recently been shown that DMF in both
wild-type and Nrf2−/−mice immunized for EAE (i) diminishes
the frequency of encephalitogenic Th1 and Th17 lymphocytes
infiltrating the CNS and (ii) induces monocyte polarization
towards anti-inflammatory M2 cells [12]. Hence, it has been
assumed that DMF exerts beneficial effects on EAE in an Nrf2-
independent manner, as well [12].
Like many other autoimmune inflammatory diseases, MS
is more frequent among women than men [20]. However,
considering the disease progression, males are more likely to
display a progressive disease, poor recovery after initial at-
tacks, and a more malignant course, even after controlling
for sex differences in the age at onset and other confounding
variables [20]. Sexual dimorphism in the clinical severity of
EAE has also been shown [21, 22]. In young adult Dark
Agouti (DA) EAE model, which replicates early inflammato-
ry stage of human disease, the maximum neurologic deficit
and severity of disease is more pronounced in males than in
age-matched females [22]. Additionally, immunopathogenic
differences at the level of target organ contributing to this
dimorphism have been described [22]. The latter seems to be
particularly important as the clinical expression of organ-
specific autoimmune diseases, including EAE and MS, is
largely controlled at the target organ level [23, 24].
However, despite the evidence of sex disparities in the patho-
genesis and clinical outcome of EAE, the efficacy of neither
immunomodulatory nor anti-oxidant drugs has been tested in
this experimental model. On the other hand, although the in-
fluence of sex on effects of some immunomodulatory drugs
(e.g., IFNβ, glatiramer acetate, fingolimod) on clinical
outcomes of the human disease has been observed, the limi-
tation of subgroup analysis design made it difficult to draw
reliable conclusions on the direction or the extent of the sex-
based effects [25]. However, data on sex differences in the
efficacy of anti-oxidants on MS are lacking. Finally, although
the efficacy of BG12, an anti-oxidant acting also as immuno-
modulator, on MS was studied in two studies incorporating
subjects of both sexes, no statistical tests for interaction be-
tween sex subgroups were performed [26, 27].
Having in mind the all aforementioned, the present study
was undertaken to investigate if there is sex-specific influence
of immunomodulatory/anti-oxidant agents on clinical out-
come of EAE in DA rats. We chose DMF, an oral fumaric
acid ester formulated as BG12 and marketed as Tecfidera®
(Biogen Idec, 2013), considering its mechanism of action. The
drug has been recently approved in the USA, Australia,
Canada, and the European Union as a first-line treatment for
patients suffering from relapsing forms ofMS. Our choice was
additionally motivated by data indicating that (i) DMFmetab-
olites identified in humans are also found in rats, and (ii) there
are no sex differences in the metabolic profile of DMF when
male and female rats are administered with comparable
amount of this ester (European Medicines Agency 26
November 2013 EMA/800904/2013 Corr. 1 Committee for
Medicinal Products for Human Use (CHMP) Assessment re-
port: Tecfidera, http://www.ema.europa.eu/ema/index.jsp?
curl=pages/medicines/human/medicines/002601/human_
med_001657.jsp&mid=WC0b01ac058001d124). Indeed, in a
preliminary experiment, DMF showed sex-specific efficacy in
moderating the clinical outcome of immunization for EAE.
Upon showing sex bias in the efficacy of DMF, the research
was continued to examine putative differences in DMF influ-
ence on T lymphocyte- and myeloid cell-dependent mecha-
nisms determining the degree of spinal cord (SC) inflamma-
tion and oxidative damage between female and male DA rats
immunized for EAE.
Material and Methods
Animals
Three-month-old DA rats of both sexes were obtained from a
breeding colony in the animal facility of the Immunology
Research Centre BBranislav Janković^ (Belgrade, Serbia).
Rats were maintained under a 12-h light/dark cycle in a
temperature-controlled environment. Standard laboratory food
and tap water ad libitumwere given throughout the duration of
the experiment. All experimental procedures and animal care
were performed in accordance with the Directive 2010/63/EU
of the European Parliament and of the Council on the
protection of animals used for scientific purposes (revising
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Directive 86/609/EEC) and approved by the Institutional
Animal Care and Use Committee.
EAE Induction and Evaluation
To induce active EAE, rats were administered with 100 μL of
an emulsion made of equal volumes of rat SC homogenate in
phosphate-buffered saline (PBS) and complete Freund’s adju-
vant (CFA) containing 1 mg/mL of heat-killed and dried
H37Ra Mycobacterium tuberculosis (Sigma-Aldrich Chemie
GmbH, Taufkirchen, Germany) followed by an injection of
0.25 mL of 5 × 108 Bordetella pertussis (Institute of
Virology, Vaccines and Sera BTorlak^, Belgrade, Serbia), as
previously described [22, 28]. This immunization protocol in
DA rats induces acute monophasic disease followed by full
recovery of all animals. The severity of neurological deficit
and body weight was recorded daily by two independent ex-
perienced observers blind to animal sex and treatment.
Neurological deficit was scored as follows: 0, no clinical
signs; 0.5, distal tail atony; 1, complete tail atony; 2,
paraparesis; 3, paraplegia; 4, tetraplegia or moribund state.
None of the rats reached moribundity during the studies. For
animals that developed neurological signs of EAE, mashed
food and water were positioned lower to facilitate access to
food and hydration and thereby to improve welfare assistance
and clinical status. None of the rats experienced reduction in
body weight greater than 10%.
Experimental Design
Rats of both sexes were randomly assigned to either DMF
treatment (+DMF groups) or vehicle (0.08% hydroxypropyl
methylcellulose) administration (−DMF groups). DMF
(100 mg/kg body weight (BW), Sigma-Aldrich Chemie
GmbH) in 0.08% hydroxypropyl methylcellulose was admin-
istered daily by oral gavage. The dose was chosen based on
data indicating that DMF at the dose of 100 mg/kg body
weight was efficient in controlling clinical signs of EAE in
rats (European Medicines Agency 26 November 2013 EMA/
800904/2013 Corr. 1 Committee for Medicinal Products for
Human Use (CHMP) Assessment report: Tecfidera, http://
www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/
human/medicines/002601/human_med_001657.jsp&mid=
WC0b01ac058001d124) and our preliminary experiment.
The preliminary experiment showed that DMF at this
particular dose reduces clinical signs of EAE, in a sex-
specific way (Fig. 1). Control rats (−DMF groups) received
a similar volume of vehicle daily by oral gavage. Considering
our experience and experience of other research groups [29]
indicating a high sensitivity of EAE model to stress, to mini-
mize the impact of stress imposed by oral gavage, all rats were
administered with vehicle over 3 days before the immuniza-
tion for EAE. From the day of immunization, the treatment
continued with vehicle or DMF until the 15th day post-
immunization (d.p.i.), when clinical signs of EAE were at
the maximum (the peak of EAE). On the 15th d.p.i., rats were
sacrificed through transcardial perfusion. Prior to the per-
fusion, the animals were deeply anesthetized with an in-
traperitoneal injection of ketamine (Ketamidor, Richter
Pharma AG, Wels, Austria; 100 mg/mL)/xylazine
(Xylased, Bioveta, Ivanovice na Hané, Czech Republic;
20 mg/mL) anesthetizing cocktail [80 mg/kg BW of ke-
tamine /8 mg/kg BW xylazine].
Following the perfusion, SCs were collected for (i) isola-
tion of mononuclear cells for flow cytometry analysis (FCA)
and proinflammatory and anti-inflammatory/immunomodula-
tory mediator/marker quantification using NO and urea assays
(six rats/sex/experiment) and (ii) RT-qPCR quantification of
proinflammatory and anti-inflammatory/immunomodulatory
mediator/marker expression and redox status parameter mea-
surement by biochemical analyses (six rats/sex/treatment). For
biochemical analyses, SC tissue was cut into pieces and quick-
ly frozen in liquid nitrogen and stored at −80 °C. For each of
these two sets of analyses, rats were chosen randomly, but
taking care to secure that the mean maximal score was com-
parable between sex- and treatment-matched groups subjected
to these two sets of analyzes. Prior to the perfusion blood
being taken, centrifuged at 2000g for 15 min at 4 °C to obtain
plasma for redox status analyses (six rats/sex/experiment).
Plasma was stored at −80 °C until assayed.
Antibodies and Immunoconjugates
For immunolabeling, the following monoclonal antibodies
(mAbs) were used: phycoerythrin (PE)-conjugated mouse
anti-rat CD4 (clone OX-38), biotin-conjugated mouse
anti-rat CD134 (clone OX-40), PE-conjugated mouse
anti-rat ED2 (CD163; clone HIS36), biotin-conjugated
mouse anti-rat CD45 (clone OX-1), PE-conjugated rat
anti-mouse IL-17A (clone TC11-18H10), fluorescein iso-
thiocyanate (FITC)-conjugated mouse anti-rat IFN-γ
(clone DB-1), peridinin-chlorophyll protein (PerCP)-con-
jugated mouse anti-rat TCRαβ (clone R73). All these
mAbs were purchased from BD Biosciences, San Jose,
CA, USA. In immunophenotyping, the following mAbs
were also included: Alexa Fluor® 647-conjugated anti-
rat TCRαβ (clone R73, Biolegend, San Diego, CA,
USA); FITC-conjugated mouse anti-rat CD11b (clone
OX-42, Serotec, Oxford, UK); goat polyclonal anti-rat
CD83 (Santa Cruz Biotechnology, Inc., Dallas, TX,
USA); and Alexa Fluor® 647-conjugated mouse anti-rat
GM-CSF (clone 83308, Novus Biologicals, Littleton, CO,
USA). As secondary step reagents, PerCP Streptavidin
(BD Biosciences) and PE-conjugated donkey anti-goat
IgG (Santa Cruz Biotechnology, Inc.) were used.
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Isolation of Mononuclear Cells
To obtain single-cell mononuclear cell suspensions, SC
tissue was meshed through 70-μm nylon cell strainer
(BD Biosciences, Erembodegem, Belgium) submerged
in ice-cold RPMI 1640 medium supplemented with 5%
fetal calf serum (FCS). Thereby obtained single-cell sus-
pensions were then fractioned on a discontinuous 40/70%
Percoll gradient at 1000×g for 50 min. Mononuclear cells
from the interface were collected and counted using an
improved Neubauer hemocytometer.
Cell Staining and FCA
Surface and Intracellular Antigen Immunostaining
For analyses of surface antigen expression, cells were incubated
with saturating concentrations of either fluorochrome-labeled
mAbs or biotin-conjugated/unconjugated Abs for 30 min and
washed in PBS supplemented with 2% FCS and 0.1% NaN3
(FACS buffer).When biotin-conjugated/unconjugatedAbswere
applied, cells were incubated with appropriate second-step re-
agents for additional 30 min, washed, and collected for FCA.
Fig. 1 DMF reduced themaximum clinical score and severity index of EAE
in rats of both sexes leading to the loss of the sexual dimorphism. In female
and male rats, active EAE was induced by injection of rat spinal cord (SC)
homogenate in complete Freund’s adjuvant. Rats subjected to the
immunization were administered with 100 mg/kg BWof DMF (+DMF) or
vehicle (−DMF) by oral gavage, daily, from the day of immunization. To
minimize stress induced by oral gavage, all animals were pretreated with
vehicle for 3 days before the immunization. The neurological signs of EAE
were scored for 21 (experiment 1) or 15 days (experiment 2) as described in
BMaterial and Methods.^ Line graph indicates the daily mean clinical
score ± S.E.M for −DMF and +DMF female and male rats combined from
experiments 1 and. Please note that 12 out of 18 rats/sex/treatment were
sacrificed at the peak of the disease (white arrow) for spinal cord analyses
(experiment 2). The incidence, the day of neurological sign appearance
(onset), duration of the clinical disease (duration), maximum clinical score
(calculated by adding maximum scores of individual diseased rats and
divided by the number of diseased rats), and severity index (calculated by
dividing the cumulative clinical scores by the number of days with clinical
signs of EAE) of EAE are presented as means ± S.E.M in the table.
Experiment 1: Two-way ANOVA showed significant interaction between
the effects of treatment and sex for the maximum clinical score
(F(1,15) = 5.166; p ≤ 0.05) and severity index (F(1,15) = 5.214; p ≤ 0.05).
Experiment 2: Two-way ANOVA showed significant interaction between
the effects of treatment and sex for the maximum clinical score
(F(1,34) = 6.28; p ≤ 0.05). #p ≤ 0.05; ##p ≤ 0.01; ###p ≤ 0.001; #Female vs
Male; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; *+DMF vs sex-matched −DMF
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To determine cell apoptosis, after surface labeling to
identify CD4+TCRαβ+ lymphocytes, SC cells were
washed with PBS and then with Annexin V binding buff-
er (BD Pharmingen). After washing, the cells were incu-
bated with 5 μL of Annexin V-FITC (BD Pharmingen) for
15 min at room temperature in the dark and collected for
FCA [28].
For cytokine production analyses, freshly isolated SC cells
were cultured in 24-well plates (Sarstedt AG&Co., Nümbrecht,
Germany) at a concentration of 106 cells/mL in culture medium
supplemented with 200 ng/mL phorbol 12-myristate 13-acetate
(PMA, Sigma-Aldrich Chemie GmbH) and 400 ng/mL
ionomycin (Sigma-Aldrich Chemie GmbH) and 3 μg/mL of
brefeldin A (eBioscience). The culture medium consisted of
RPMI 1640 supplemented with 2 mM L-glutamine (Serva,
Heidelberg, Germany), 1 mM sodium pyruvate (Serva),
100 units/mL penicillin (ICN, Costa Mesa, CA, USA),
100 μg/mL streptomycin (ICN), and 10% FCS (Gibco, Grand
Island, NY, USA). The plates were incubated in humidified
atmosphere of 5% v/v CO2 for 4 h at 37 °C. Following incuba-
tion, the cells were harvested and subjected to cell surface anti-
gen immunostaining. Following staining for surface antigen de-
tection, the cells were washed and fixed/permeabilized over-
night at 4 °C, using the solutions from fixation/
permeabilization buffer kit (eBioscience; http://www.
ebioscience.com/resources/best-protocols/flow-cytometry-
protocols.htm). Next, the cells were washed using appropriate
permeabilization buffer (eBioscience), incubated with
fluorochrome-conjugated anti-IFN-γ/anti-IL-17/anti-GM-CSF
mAb cocktails for 30 min at room temperature in the dark,
and then washed again and collected for FCA.
FCA
For FCA, 50,000 cellular events per sample were ac-
quired on a FACSVerse flow cytometer (Becton
Dickinson, Mountain View, CA, USA) using FACSuite
v1.0.5.3841 software (Becton Dickinson). FlowJo soft-
ware version 7.8. (TreeStar Inc., Ashland, OR, USA)
was used to analyze the data for percentage of marker-
positive cells and mean fluorescence intensity (MFI).
Dead cells and debris were excluded from the analyses
by selective gating based on forward scatter (FSC) and
side scatter (SSC), whereby background staining level
for each fluorochrome type was defined using non-
specific IgG isotype-matched controls. Fluorescence mi-
nus one (FMO) controls were applied to set gating
boundaries [28]. For setting cutoff for Annexin V stain-
ing, apart from negative (unstained cells) control, posi-
tive biological comparison control (lymphocytes treated
with 10% v/v dimethyl sulfoxide for 60 min at 37 °C)
was used.
RT-qPCR Quantification of Inducible Nitric Oxide
Synthase, Arginase, and Cytokine mRNAs
SC tissue samples were harvested using nucleic acid purifica-
tion lysis solution (Applied Biosystems, Foster City, CA,
USA) and immediately stored at −70 °C until RNA purifica-
tion. Total RNA from SC tissue homogenates was extracted
using ABI Prism 6100 Nucleic Acid PrepStation system
(Applied Biosystems) and Total RNA Chemistry Starter Kit
(Applied Biosystems). The procedure included DNAse treat-
ment to ensure that no genomic DNA contamination was
present. Isolated RNA was converted to complementary
DNA (cDNA) using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems), in 20-μL reactions
ran under optimal conditions (10 min, 25 °C; 120 min,
37 °C; 5 s, 85 °C). For analysis of inducible nitric oxide
synthase (iNOS), arginase, heme oxygenase 1 (HO-1), nuclear
factor, erythroid 2-like 2 (Nrf2) and cytokines (IL-1β and
IL-6) messenger RNA (mRNA) expression, triplicate
25-μL RT-qPCR reactions, containing 1× TaqMan Gene
Expression Master Mix (Applied Biosystems), 1× mix of
premade primer and hydrolysis probe sets (TaqMan Gene
Expression Assays, Applied Biosystems), and 5 μL of
cDNA template, were ran under the default Applied
Biosystems 7500 Real-Time PCR System conditions
(2 min at 50 °C, 10 min at 95 °C, followed by 40 cycles
consisting of 15 s at 95 °C and 1 min at 60 °C incubations
each). The following gene expression assays were used:
iNOS (Nos2; Rn00561646_m1), arginase (Arg-1;
Rn00691090_m1), HO-1 (decycling) 1 (Hmox1;
Rn00561387_m1), Nrf2 (Nrf2, also called Nfe2l2;
Rn00582415_m1), IL-1β (Il1b; Rn99999009_m1), IL-6
( I l 6 ; R n 9 9 9 9 9 0 11 _m1 ) , a n d β - a c t i n (A c t b ;
Rn00667869_m1). Relative quantification of mRNA level
was done using SDS v1.4.0. software (Applied
Biosystems) and 2−ΔΔCt method with β-actin as a
normalizer.
NO Production and Arginase Activity in SCMononuclear
Cells
Mononuclear cells retrieved from SC (1 × 105/well)
were cultured in 96-well plates in RPMI 1640 supple-
mented with 5% FCS overnight at 37 °C in a humidi-
fied 5% v/v CO2 atmosphere. Supernatants were assayed
for the level of NO by Griess reagent, as previously
described [30]. The concentration of nitrite in the sam-
ples was calculated using a NaNO2 (1–80 μM) as a
standard. The cells were collected and processed for
arginase activity by the method based on the urea pro-
duction as previously described [29]. The concentration
of urea in the samples was calculated according to the
standard curve (1–80 μM of urea).
Mol Neurobiol (2018) 55:3755–3774 3759
Analyses of Redox Status
For biochemical analyses of redox status, frozen SC tissue
was diluted 10 times in 0.1 M phosphate buffer (pH 7.4, sup-
plemented with 11.5 mg/mL KCl), homogenized using a ho-
mogenizer (Thomas Scientific, Swedesboro, NJ, USA) and
centrifuged at 12,000g for 40 min. Thereby obtained superna-
tants were used for analyses. All the steps were carried out at
0–4 °C. The level of O2
• − was estimated according to the rate
of yellow nitroblue tetrazolium reduction to blue diformazan
[31].
Xanthine oxidase (XO) was determined spectrophotomet-
rically by using the rate of urate formation from hypoxanthine
measuring absorbance increase at 290 nm as previously de-
scribed [7]. A unit of activity is defined as forming of 1 μMof
urate per minute at 25 °C.
Cu/Zn superoxide dismutase (SOD) activity was measured
using slightly modified method of Misra and Fridovich [32],
based on the ability of SOD to inhibit auto-oxidation of epi-
nephrine in alkaline medium. The enzyme activity is calculat-
ed as percentage of inhibition of epinephrine auto-oxidation
[7].
Glutathione (GSH) concentration was assayed according to
its reaction with 5,5′-dithiobis-2-nitrobenzoic acid [7].
Spectrophotometric determination of a yellow complex 5-
thio-2-nitrobenzoate at 412 nm was performed after the
deproteinization with sulfosalicylic acid. Reduced glutathione
in a range from 0.5 to 2 μmol/L was used for the calibration.
Malondialdehyde (MDA) concentration was measured
using the thiobarbituric acid-reactive substance (TBARS) as-
say employing the molar absorption coefficient of
1.56 × 105 M−1 cm−1 and spectrophotometry at 535 nm [33].
Advanced oxidation protein products (AOPP) concentra-
tion was assayed by measuring the absorbance at 340 nm of
complex formed in its reaction with glacial acetic acid
potassium-iodide [34]. Chloramine T, a compound exhibiting
specific absorption maximum at 340 nm, was used as a stan-
dard with concentration range from 10 to 100 μmol/L.
Total pro-oxidant capacity (TOC) was measured by a spec-
trophotometric method introduced by Erel [35] and slightly
modified in our laboratory [36]. The method is based on the
ability of all oxidants such as hydrogen peroxide and lipid
hydroperoxide to oxidize the ferrous ion-o-dianisidine com-
plex to ferric ion. Second reaction relies on the ferric ion
reaction with xylenol orange in an acidic medium, which
makes a colored complex. The intensity of color is proportional
with the total amount of oxidant molecules present in the sam-
ple. The assay is calibrated with hydrogen peroxide in concen-
tration ranged from 10 to 200 μmol/L.
Total anti-oxidant capacity (TAC) was measured by a spec-
trophotometric method using 10 mmol/L colored 2,2′-
azinobis-(3-ethylbenzothiazoline-6-sulfonic acid radical cat-
ion (ABTS(*+)) as a chromogen [37]. The ABTS(*+) is
decolorized by anti-oxidants according to their concentrations
and anti-oxidant capacities. This change in color is measured
as a change in absorbance at 660 nm. The reaction is calibrated
with Trolox, vitamin E water-soluble analog, and the assay
results are expressed in micromoles Trolox equivalent/L.
Pro-oxidant-anti-oxidant balance (PAB) was determined by
a modified PAB test using 0.6% 3,3′,5,5′-tetramethylbenzidine
(TMB) in dimethyl sulfoxide as a chromogen [7, 38]. PAB test
measures H2O2 concentration in an anti-oxidant environment,
because TMB could react at the same time with H2O2 (reaction
catalyzed with peroxidase enzyme), so as with reductive sub-
stances such as uric acid (chemical, non-catalyzed reaction).
Enzymatic reaction causes TMB oxidation to blue product,
whereas chemical reduction leads to non-colored product.
The net reaction is exactly the difference between two opposite
oxido-reductive processes at the same substrate. Reaction cali-
bration is performed with the mixture of H2O2 and uric acid in
different ratios, defined from 0 to 100%.
Biochemical parameters in SC tissue were normalized per
gram protein in the sample [39]. Spectrophotometric assays
were performed with a continuous spectrophotometer
(Pharmacia LKB, Cambridge, UK) with the exception of as-
says for determination of TAC and TOC which were imple-
mented on ILAB 300 Plus analyzer (Instrumentation
Laboratory, Milan, Italy).
Statistical Analysis
The quantitative data were analyzed by two-way ANOVA
(treatment × sex) followed by Bonferroni as post hoc test.
Data were presented as mean ± S.E.M. All statistical analyses
were performed using GraphPad Prism 5 software (GraphPad
Software, Inc., La Jolla, CA, USA). Values of p ≤ 0.05 were
considered significant.
Results
DMF was more Efficient in Reducing the Severity of EAE
in Males
As shown in the preliminary experiment (experiment 1), when
the neurological signs of EAE were followed until the
21st d.p.i. (Fig. 1), irrespective of treatment, rats of both sexes
immunized for EAE developed monophasic self-limiting dis-
ease. The incidence of the disease was higher in female than
male −DMF rats in experiment 1, and in subsequent experi-
ment (experiment 2) performed to examine immunological
and oxidative stress parameters in SC at the peak of EAE
(Fig. 1). In both the experiments, the first neurological signs
of EAE appeared later (p ≤ 0.05 and p ≤ 0.001 in experiments
1 and 2, respectively) in male than in female −DMF rats.
Besides, the symptomatic stage of the disease was of shorter
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duration in male when compared with female −DMF rats, but
this difference did not reach statistical significance (Fig. 1).
However, the maximum neurological deficit was greater
(p ≤ 0.05 and p ≤ 0.001 in experiments 1 and 2, respectively)
in male than in female −DMF rats (Fig. 1). The clinical sever-
ity index calculated by dividing the cumulative clinical scores
by the number of days with clinical signs of EAE [40] also
suggested more severe (p ≤ 0.01) disease in male −DMF rats
than in their female counterparts (Fig. 1).
Oral application of DMF diminished the incidence of EAE
in both female and male rats, so in both the experiments, it did
not significantly differ between sexes (Fig. 1). However, irre-
spective of sex, DMF did not influence the appearance of the
first neurological signs of EAE (Fig. 1). DMF reduced
(p ≤ 0.05) the duration of the clinical disease in female rats,
whereas it was ineffective in this respect in their male coun-
terparts (Fig. 1). Consequently, the duration of clinical disease
was comparable in female and male +DMF rats (Fig. 1). In
both the experiments, DMF attenuated the maximum neurolog-
ical deficit in female (p ≤ 0.05) and male rats (p ≤ 0.01 and
p ≤ 0.001 in experiments 1 and 2, respectively), but to a greater
extent in males (Fig. 1). Thus, the maximum neurological def-
icit did not significantly differ between female and male +DMF
rats (Fig. 1). Additionally, judging by the clinical severity in-
dex, DMF reduced the severity of EAE in both female
(p ≤ 0.05) and male (p ≤ 0.001) rats, abolishing the sexual
dimorphism observed in −DMF rats (Fig. 1).
Sexually Dimorphic
Immunomodulatory/Anti-inflammatory Effects of DMF
in EAE
DMF was more Efficient in Diminishing Number
and Reactivation of CD4+ T Lymphocytes Infiltrating SC
of Male than Female Rats Immunized for EAE
At the peak of EAE, in accordance with the greater maximum
neurological deficit, more (p ≤ 0.05) mononuclear cells were
retrieved from SC of male (3.63 × 106 ± 0.09 × 106) −DMF
ra t s compa r ed w i t h t h e i r f ema l e coun t e r pa r t s
(2.70 × 106 ± 0.06 × 106), and among them was found more
(p ≤ 0.001) CD4+ T lymphocytes, the major drivers of EAE
development in rodents immunized with CNS antigen(s) in
CFA [41] (Fig. 2a). Irrespective of sex, DMF diminished
(p ≤ 0.001) the number of mononuclear cells isolated from
f ema l e ( 2 . 0 9 × 10 6 ± 0 . 0 8 × 10 6 ) a n d ma l e
(1.97 × 106 ± 0.88 × 106). Additionally, fewer (p ≤ 0.001)
CD4+ T lymphocytes were recovered from +DMF compared
with sex-matched −DMF rats, but this effect of DMF was
more prominent in males (Fig. 2a). Consequently, CD4+ T
lymphocyte number was comparable in SC mononuclear
cell suspensions from female and male +DMF rats
(Fig. 2a).
Next, the expression of CD134 on CD4+TCRαβ+ lym-
phocytes was examined. This molecule was used as a marker
of CD4+ T lymphocyte reactivation based on findings indi-
cating that encephalitogenic effector CD4+ T lymphocytes
down-regulate its expression before crossing the blood-brain
barrier [42]. The frequency of re-activated CD134+ cells
among CD4+ TCRαβ+ lymphocytes (p ≤ 0.01), and CD134
surface density (judging by CD134 MFI) (p ≤ 0.001), were
higher in male compared with female −DMF rats (Fig. 2b).
Irrespective of sex, DMF diminished (p ≤ 0.001) not only the
frequency of CD134+ cells among CD4+ TCRαβ+ lympho-
cytes but also CD134 surface density on CD4+TCRαβ+ lym-
phocytes, judging by CD134 MFI (Fig. 2b). The latter effect
was more prominent in males than in females, leading to the
loss of the sexual dimorphism observed in −DMF rats (Fig. 2b).
Considering the previous findings and proapoptotic influ-
ence of DMF on purified human T lymphocytes [43], CD4+ T
lymphocytes were also investigated for the frequency of apo-
ptotic Annexin V+ cells. Their frequency was lower
(p ≤ 0.001) in male compared with female −DMF rats
(Fig. 2c). Contrary to expectations, irrespective of sex, DMF
did not significantly influence the frequency of Annexin V+
cells among CD4+TCRαβ+ lymphocytes (Fig. 2c).
DMF was more Efficient in Diminishing the Frequency
of Highly Pathogenic IFN-γ/GM-CSF-Producing T
Lymphocytes in SC of Male Rats Immunized for EAE
Having in mind that DMF diminishes the frequencies of path-
ogenic T lymphocytes producing IL-17 (IL-17+) in mouse
EAE model [12], their frequency in PMA- and ionomycin-
stimulated T lymphocytes isolated from SC was examined.
At the peak of EAE, IL-17+ cell frequency and number within
T lymphocytes were higher (p ≤ 0.001) in SC from male
compared with female −DMF rats (Fig. 3a). DMF reduced
(p ≤ 0.001) their frequency and number in rats of both sexes
(Fig. 3a). However, this effect of DMFwas more prominent in
males, so IL-17+ cell frequency among T lymphocytes and
their number did not significantly differ between female and
male +DMF rats (Fig. 3a).
Next, considering several findings, IL-17+ T lymphocytes
were examined for their cytokine profile. Namely, IL-17+
CD4+ T lymphocytes are shown to exhibit a great degree of
context-dependent plasticity, so they are capable of co-
producing IFN-γ and GM-CSF [44–46]. Additionally,
IFN-γ- and GM-CSF-producing (IFN-γ+GM-CSF+) IL-17+
T cells are found to be highly pathogenic in mouse EAE
models [44, 45] and positively correlated with severity of
neurological deficit in DA rat EAE model [22]. In accordance
with more severe neurological deficit, both the frequency of
IFN-γ+GM-CSF+ cells among IL-17+ T lymphocytes and
their number were higher (p ≤ 0.001) in male than in female
−DMF rat SC (Fig. 3b). In rats of both sexes, DMF diminished
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the frequency of IFN-γ+GM-CSF+ cells among IL-17+ T
lymphocytes (p ≤ 0.05 and p ≤ 0001 in female and male rats,
respectively) and their number (p ≤ 0.001) in SC (Fig. 3b).
These DMF effects were more pronounced inmale rats than in
their female counterparts. Consequently, we failed to find any
significant sex differences in either the frequency of IFN-γ+
GM-CSF+ cells among IL-17+ T lymphocytes from SC of
+DMF rats or in their number (Fig. 3b). Given that IL-1β
and IL-6 have been implicated in differentiation of pathogenic
IFN-γ+GM-CSF+ cells [47], their expression in SC tissue
was also examined. In agreement with the higher frequency
of IFN-γ+GM-CSF+ cells among IL-17+ T lymphocytes
from male compared with female −DMF rats, IL-1β mRNA
expression was upregulated (p ≤ 0.001) in their SC, whereas
Fig. 2 DMF was more efficient
in decreasing the number of
CD4+ T lymphocytes infiltrating
spinal cord of male rats
immunized for EAE. Flow
cytometry dot plots show a CD4
vs TCRαβ staining of
mononuclear cells (MNC)
retrieved at the peak of EAE from
spinal cord (SC) of female and
male rats administered with DMF
(+DMF) or vehicle (−DMF) and
b CD134 and c Annexin V
staining of CD4+TCRαβ+
lymphocytes gated as shown (a).
Scatter plots present a the number
of CD4+TCRαβ+ lymphocytes
and the frequency of b CD134+
and c Annexin V+ cells among
CD4+TCRαβ+ cells in SC from
female and male +DMF and
−DMF rats. b Numbers in the
table represent CD134 mean
fluorescence intensity (MFI) on
CD134+CD4+ TCRαβ+ cells.
Results are from one of two
similar experiments each
comprising six rats/group. Data
are presented as mean ± S.E.M.
Two-way ANOVA showed
significant interaction between
the effects of treatment and sex
for CD4+TCRαβ+ lymphocyte
number (F(1,20) = 58.72;
p ≤ 0.001) and CD134 MFI
(F(1,20) = 13.95; p ≤ 0.01).
**p ≤ 0.01; ***p ≤ 0.001; aMale
vs female; b+DMF vs sex-
matched −DMF
3762 Mol Neurobiol (2018) 55:3755–3774
the expression of IL-6 mRNA was comparable to that mea-
sured in females (Fig. 3c). Irrespective of sex, DMF diminished
(p ≤ 0.001) the expression of IL-1β and IL-6 mRNAs (Fig. 3c).
DMF was particularly efficient in reducing IL-1β mRNA ex-
pression in males (approx. twofold in females vs approx. three-
fold in males). The expression of IL-βmRNA remained greater
(p ≤ 0.001) in male than in female +DMF rats, whereas that of
IL-6 mRNA was lower in males, but this difference did not
reach statistical significance (Fig. 3c).
DMF was more Efficient in Increasing the Frequency
of CD163+ Cells among CD11b+ CD45+TCRαβ− SC
Mononuclear Cells and Upregulating their CD83 Surface
Density in Male Rats Immunized for EAE
Considering (i) bidirectional communication between enceph-
alitogenic CD4+ T lymphocytes and resident-/blood-borne
myeloid cells, so that they affect each other’s activation and
differentiation/polarization [48–50] and (ii) M2 polarizing
Fig. 3 DMF was more efficient in diminishing the percentage of highly
pathogenic multiple-cytokine-producing T lymphocytes infiltrating
spinal cord of male rats immunized for EAE. Flow cytometry dot plots
indicate a IL-17 vs TCRαβ staining of mononuclear cells (MNC)
retrieved at the peak of EAE from spinal cord (SC) of female and male
rats administered with DMF (+DMF) or vehicle (−DMF) and b IFN-γ vs
GM-CSF staining of IL-17+TCRαβ+ lymphocytes gated as shown in a
dot plots. Scatter plots indicate a the frequency of IL-17+TCRαβ+
lymphocytes among SC MNC (left) and their number (right) and b the
frequency of IFN-γ+ GM-CSF+ cells among IL-17+TCRαβ+
lymphocytes (left) and their number (right) in MNC suspensions from
SC of female and male −DMF and +DMF rats. c Bar graphs indicate the
fold change in left IL-1β and right IL-6 mRNA expression in SC tissue
from female and male +DMF rats and male −DMF rats relative to female
−DMF rats, as determined by RT-qPCR at the peak of EAE. Results are
normalized to β-actin expression. Results are from one of two similar
experiments each comprising six rats/group. Data are presented as
mean ± S.E.M. Two-way ANOVA showed significant interaction be-
tween the effects of treatment and sex for frequency of IL-17+ T cells
(F(1,20) = 13.40; p ≤ 0.01); number of IL-17+ T cells (F(1,20) = 82.59;
p ≤ 0.001); frequency of IFN-γ+ GM-CSF+ T cells (F(1,20) = 20.012;
p ≤ 0.001), number of IFN-γ+ GM-CSF+ IL-17+ T cells
(F (1 ,20) = 71.03; p ≤ 0.001) and IL-1β mRNA expression
(F(1,20) = 36.79; p ≤ 0.001). *p ≤ 0.05; ***p ≤ 0.001
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effects of DMF on SCmonocytes from experimental models of
autoimmune diseases and macrophage cell lines [12, 51], SC
microglia/macrophages were investigated for the expression of
M2 polarization markers. To identify microglia/macrophages,
SC mononuclear cells were subjected to triple CD11b/CD45/
TCRαβ immunostaining. They were subjected to the triple
instead of CD11b/CD45 double immunostaining as previously
suggested [28] because pathogenic T lymphocytes infiltrating
SC in EAE are also shown to express CD11b [52, 53]. CD11b+
CD45+TCRαβ− cells were examined for the expression of
CD163 molecule, as it is shown to be a marker of microglia
and macrophages with anti-inflammatory M2 properties in au-
toimmune neuroinflammation [54]. More important, in acute
rat EAE model CD163+ cells are suggested to be of crucial
importance in restricting neuroinflammation, and consequently
recovery from paralysis [54]. The frequency of CD163+ cells
was similar among CD11b+CD45+TCRαβ− cells from SC of
male and female −DMF rats (Fig. 4a). DMF elevated
(p ≤ 0.001) their frequency among CD11b+CD45+TCRαβ−
cells in both sexes, but this effect was more pronounced in
males (Fig. 4a). Consequently, the frequency of CD163+ cells
was higher (p ≤ 0.001) among CD11b+CD45+TCRαβ− cells
from SC of male +DMF rats compared with their female coun-
terparts (Fig. 4a).
Considering that in autoimmune neuroinflammation CD163+
microglia/macrophages are found to be actively phagocyting
cells [54], and that apoptotic cell-derived membrane vesicles
are shown to induce CD83 upregulation [55], the expression of
CD83 on CD11b+ CD45+TCRαβ− cells was also investigated.
The frequency of cells expressing surface CD83 was similar
among CD11b+CD45+TCRαβ− SC cells from male and fe-
male −DMF rats (Fig. 4b). DMF induced a similar sex-specific
pattern of changes in the frequency of CD83+ cells among
CD11b+CD45+TCRαβ− SC cells to that observed in the fre-
quency of CD163+ cells. Namely, their frequency increased
(p ≤ 0.001) in female (approx. threefold) and male (approx.
fivefold) +DMF rats of both sexes, so it was higher (p ≤ 0.001)
in male +DMF rats (Fig. 4b). Judging by CD83MFI, DMF also
upregulated the surface density of CD83 on CD83+CD11b+
CD45+TCRαβ− cells from rats of both sexes. Consequently,
CD83 surface density was also higher (p ≤ 0.001) on CD83+
CD11b+CD45+TCRαβ− cells from male rats (Fig. 4b).
Being aware that markers of anti-inflammatory myeloid
cells depend on the disease model and the organ from which
they are isolated [56], we also examined (i) the expression of
arginase-1 (Arg-1), the enzyme catalyzing the hydrolysis of L-
arginine to ornithine and urea, in SC and (ii) the production of
urea in overnight SC mononuclear cell cultures. We decided
for Arg-1 as it is suggested to be the best characterized marker
of the anti-inflammatory macrophages/microglia in the CNS
[57, 58], and, particularly, in acute rat EAE model [59]. The
amount of Arg-1 mRNA in SC from female and male -DMF
rats did not significantly differ (Fig. 5a). Consistent with the
frequency of CD163+ cells, DMF upregulated the expression
of Arg-1 mRNA in SC from both female (p ≤ 0.05) and male
(p ≤ 0.001) rats, but DMF was more efficient in this respect in
males (Fig. 5a). The analysis of urea concentration in SC
mononuclear cell cultures showed comparable concentration
of urea in the cultures from female and male −DMF rats
(Fig. 5a). However, compared with SC mononuclear cell cul-
tures from −DMF rats, in those from +DMF rats the concen-
tration of urea was elevated (p ≤ 0.05 in female and p ≤ 0.001
male cultures, respectively), and this effect of DMF was
higher (p ≤ 0.001) in male rat cultures (Fig. 5a).
Considering that, in general, mutually exclusive expression
of inducible nitric oxide synthase (iNOS, catalyzes the pro-
duction of NO from arginine) and Arg-1 in individual macro-
phages prevails [60], the expression of iNOS mRNA in SC
tissue and the production of NO in overnight SCmononuclear
cell cultures were also examined. The expression of iNOS
mRNA in SC tissue did not statistically significantly differ
between female and male −DMF rats (Fig. 5b). Irrespective
of sex, DMF diminished (p ≤ 0.05) iNOS mRNA expression
in SC tissue, so that comparable amounts of this mRNAwere
found in female and male SC tissue (Fig. 5b). The analysis of
NO production by SC mononuclear cell cultures showed
higher (p ≤ 0.05) NO concentration in the cultures from male
compared with female −DMF rats (Fig. 5b).We failed to show
statistically significant difference in NO concentration be-
tween SC mononuclear cell cultures from −DMF and +DMF
female rats (Fig. 5b). In the presence of DMF, NO concentra-
tion diminished in SC mononuclear cell cultures from rats of
both sexes, but this decrease reached statistical significance
(p ≤ 0.01) only in those from male rats (Fig. 5b).
Finally, considering that DMF is shown to favor monocyte/
macrophage polarization, at least partly, through mobilization
of anti-inflammatory Nrf2/HO-1 axis and upregulation of HO-
1 level [12, 51], the expression of Nrf2 and HO-1 mRNAs in
SC tissuewas examined. Therewere no significant differences
in the expression of mRNAs for Nrf2 and HO-1 in SC from
male compared with female −DMF rats (Fig. 5c). Irrespective
of sex, DMF augmented (p ≤ 0.001) the expression of Nrf2
andHO-1mRNAs in SC (Fig. 5c). These effects of DMFwere
more prominent in males, leading to greater (p ≤ 0.001) SC
expression of both Nrf2 and HO-1 mRNAs in male compared
with female +DMF rats (Fig. 5c).
Sexual Dimorphism in DMF Influence on Redox Status
in SC Tissue and Blood from Male Rats Immunized
for EAE
DMF was more Efficient in Reducing Oxidative Tissue
Damage in SC Tissue of Male Rats
In the second step, considering the previous finding indicating
sexually dimorphic effects of DMF on neuroinflammation,
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and data indicating that RNS and ROS represent the major
mediators in the inflammation-induced neuronal tissue dam-
age in MS and EAE [8], apart from SC cell capacity to pro-
duce NO, the generation of O2
• − in SC tissue was investigat-
ed. Indeed, the level of O2
• −, a central pro-oxidant generated
in several enzymatic and non-enzymatic reactions, was also
greater (p ≤ 0.05) in SC of male −DMF rats exhibiting more
severe disease than in their female counterparts (Fig. 6a).
DMF diminished (p ≤ 0.05 and p ≤ 0.001 in female and male
rats, respectively) SC level of O2
• − in rats of both sexes, but it
was more efficient in this respect in males (Fig. 6a).
Consequently, the level of O2
• − was comparable in SC of
female and male +DMF rats (Fig. 6a).
In accordance with the previous findings, TOC, reflecting
the overall pro-oxidant tissue potential, and consequently as-
sumed to be a comprehensive marker of the total tissue oxi-
dative stress burden, was greater in SC of male −DMF rats
compared with female rats, but this difference did not reach
statistical significance (Fig. 6a). DMF decreased TOC in SC
from both male and female rats, but this decrease reached
statistical significance (p ≤ 0.01) only in males (Fig. 6a).
Thus, TOC was similar in SC of female and male +DMF rats
(Fig. 6a).
To elucidate mechanism standing behind the previously
described phenomenon, the activity of XO, which is shown
to be the main enzyme catalyzing O2
• − generation in inflam-
matory settings [61], was examined. Its activity was greater
(p ≤ 0.001) in male than in female −DMF rat SC (Fig. 6a).
DMF reduced (p ≤ 0.001) XO activity in SC of rats of both
sexes, abrogating sexual dimorphism observed in −DMF rats
(Fig. 6a).
Based on data indicating that the imbalance between pro-
oxidants and anti-oxidants in favor of the former leads to cell
damage, some important anti-oxidant mechanisms were also
Fig. 4 DMF was more efficient in increasing the frequency of CD163+
cells among CD11b+CD45+ TCRαβ− cells and their expression of
CD83 in spinal cord of male than female rats. Flow cytometry dot plots
show a CD163 and b CD83 staining of CD11b+CD45+TCRαβ− cells
retrieved at the peak of EAE from spinal cord (SC) of female and male
rats administered with DMF (+DMF) or vehicle (−DMF). Gating strategy
for CD11b+CD45+TCRαβ– cells is shown in Supplementary Fig. 2.
Scatter plots indicate the frequency of a CD163+ and b CD83+ cells
among CD11b+CD45+TCRαβ− SC cells. b Numbers in the table
represent CD83 mean fluorescence intensity (MFI) on CD83+CD11b+
CD45+TCRαβ− cells retrieved from SC of female and male −DMF and
+DMF rats. Results are from one of two similar experiments each
comprising six rats/group. Data are presented as mean ± S.E.M. Two-
way ANOVA showed significant interaction between the effects of treat-
ment and sex for the frequency of CD163+ (F(1,20) = 44.85; p ≤ 0.001)
and CD83+ (F(1,20) = 244.7; p ≤ 0.001) cells and CD83 MFI
(F(1,20) = 30.09; p ≤ 0.001). ***p ≤ 0.001; aMale vs female; b+DMF vs
sex-matched −DMF
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examined. Given that SOD: (i) represents the major anti-
oxidant defense systems against O2
• − and (ii) plays the
critical role in the inhibition of NO oxidative inactivation
and thereby peroxynitrite (ONOO−) formation and endo-
thelial and mitochondrial dysfunction [62], its activity in
SC was examined. The higher level of O2
• −, and most
likely greater generation of NO in SC of male compared
with female −DMF rats, were accompanied by lower
(p ≤ 0.01) SOD activity (Fig. 6b). DMF enhanced SOD
activity in female (p ≤ 0.05) and male (p ≤ 0.001) rat SC
(Fig. 6b). Additionally, it led to the loss of sexual dimor-
phism in SOD activity in rat SC (Fig. 6b).
Next, considering important role of GSH-dependent anti-
oxidant enzyme system in cellular protection against ROS,
and particularly influence of DMF on GSH cellular levels
[63], its levels in SCwere also investigated. We failed to show
any significant sex difference in GSH level in SC of −DMF
rats (Fig. 6b). However, irrespective of sex, DMF increased
(p ≤ 0.001) GSH level in SC, and the magnitude of this effect
did not significantly differ between sexes (Fig. 6b).
Furthermore, SC from all animals was examined for TAC
as a comprehensive measure of the total anti-oxidant potential.
As expected from the previous analyses, TAC was lower
(p ≤ 0.05) in male than in female −DMF rat SC (Fig. 6b). In
Fig. 5 Sex-based differences in
DMF effects on the expression of
arginase-1, Nrf2 and heme
oxigenase 1 in the spinal cord
tissue of rats immunized for EAE.
Bar graphs indicate the fold
change in a arginase-1 (Arg-1); b
iNOS; c nuclear factor, erythroid
2-like 2 (Nrf2) and heme
oxigenase 1 (HO-1) mRNA
expression in spinal cord (SC)
tissue from female and male
+DMF rats and male −DMF rats
relative to female −DMF rats, as
determined by RT-qPCR at the
peak of EAE. Results are
normalized to β-actin expression.
Inserted bar graphs indicate
concentration of a urea and b NO
in overnight mononuclear SC cell
cultures from female and male
−DMF and +DMF rats. Results
are from one of two similar
experiments each comprising six
rats/group. Data are presented as
mean ± S.E.M. Two-way
ANOVA showed significant
interaction between the effects of
treatment and sex for Arg-1
(F(1,20) = 16.09; p ≤ 0.001), Nrf2
(F(1,20) = 5.926; p ≤ 0.001), and
HO-1 mRNA expression
(F(1,20) = 23.58; p ≤ 0.001), and
for urea concentration
(F(1,20) = 9.148; p ≤ 0.01).
*p ≤ 0.05; **p ≤ 0.01;
***p ≤ 0.001
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SC of +DMF rats of both sexes (p ≤ 0.01), TAC levels were
higher than in sex-matched −DMF rats (Fig. 6b). Besides,
TAC level was similar in SC of female and male +DMF rats
(Fig. 6b).
Finally, the parameters of SC oxidative damage, i.e., levels
of MDA, a marker of lipid oxidative degradation, and AOPP, a
marker of oxidative protein damage, were explored. Despite
more severe clinical EAE in male −DMF rats, MDA level in
their SC did not significantly differ from that in their female
counterparts (Fig. 6c). DMF diminished (p ≤ 0.001)MDA level
in SC of both female and male rats (Fig. 6c). The magnitude of
this effect did not significantly differ between sexes (Fig. 6c).
On the other hand, AOPP level was higher (p ≤ 0.001) in
SC of male compared with female −DMF rats (Fig. 6c). DMF
diminished (p ≤ 0.05) AOPP level only in SC of male rats, so
it did not significantly differ in SC of female and male +DMF
rats (Fig. 6c).
Sexually Dimorphic Effects of DMF on Redox Status
in Blood of Rats Immunized for EAE
Considering data from our previous study indicating multiple
correlations between SC and peripheral blood oxidative status
parameters [7], the redox status was also assessed in
circulation of rats subjected to DMF treatment. There were
no significant differences in the plasma level of either O2
• −
or TOC across experimental groups (Fig. 7a).
However, SOD activity was lower (p ≤ 0.01) in the plasma
of male −DMF rats when compared with their female coun-
terparts (Fig. 7b). DMF increased (p ≤ 0.001) its activity in
rats of both sexes, leading to the loss of sexual dimorphism
(Fig. 7b). Next, influence of sex and DMF on plasma TAC
was addressed. In agreement with SOD activity, sexual dimor-
phism was also found in the value of TAC, so it was lower
(p ≤ 0.001) in male compared with female −DMF rats
(Fig. 7b). DMF-induced changes in plasma TAC exhibited
the similar pattern to those observed in plasma SOD activity.
Specifically, the value of this parameter increased in plasma of
+DMF rats (p ≤ 0.01 and p ≤ 0.001 in female and male rats,
respectively) (Fig. 7b). Besides, DMF led to the loss of sexual
dimorphism in the TAC value (Fig. 7b).
Next, PAB was analyzed. There was no significant sex dif-
ference in the value of this parameter in −DMF rats (Fig. 7c).
However, DMF decreased (p ≤ 0.001) its value in rats of both
sexes to a similar extent (Fig. 7c). Consequently, there was no
significant sex differences in PAB in +DMF rats (Fig. 7c).
Finally, the influence of DMF on plasma MDA and AOPP
levels was examined. Neither sex nor DMF influenced plasma
Fig. 6 DMF affected redox status
in the spinal cord tissue from rats
of both sexes in a sexually
dimorphic manner. Scatter plots
show a pro-oxidant parameters:
O2
• − level, total pro-oxidant
capacity (TOC), and xanthine
oxidase (XO) activity. b Anti-
oxidant parameters: superoxide
dismutase (SOD) activity,
glutathione (GSH) level and total
anti-oxidant capacity (TAC), and
c Parameters of tissue damage:
malondialdehyde (MDA) and
advanced oxidation protein
products (AOPP) levels, at the
peak of EAE in the spinal cord
tissue of female and male rats
administered with DMF (+DMF)
or vehicle (−DMF). Results are
from one of two similar
experiments each comprising six
rats/group. Data are presented as
mean ± S.E.M. Two-way
ANOVA showed significant
interaction between the effects of
treatment and sex for O2
• −
(F(1,20) = 5.397; p ≤ 0.05), XO
(F(1,20) = 38.35; p ≤ 0.001), SOD
(F(1,20) = 55.12; p ≤ 0.001), TAC
(F(1,20) = 4.885; p ≤ 0.05), and
AOPP (F(1,20) = 12.53; p ≤ 0.01).
*p ≤ 0.05; **p ≤ 0.01;
***p ≤ 0.001
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MDA level (Fig. 7d). Plasma AOPP level was higher
(p ≤ 0.05) in male than in female −DMF rats (Fig. 7d). DMF
influenced (p ≤ 0.001) AOPP level only in male rats, leading
to a profound decrease (Fig. 7d). Consequently, its value was
comparable in female and male +DMF rats (Fig. 7d).
Discussion
The study showed that DMF administration from the day of
immunization influences EAE development in a sex-specific
manner. Consistently, DMF attenuated the severity of EAE in
Fig. 7 DMF affected redox status
in the blood from rats of both
sexes immunized for EAE.
Scatter plots show a pro-oxidant
parameters: O2
• − level and total
pro-oxidant capacity (TOC), b
Anti-oxidant parameters:
superoxide dismutase (SOD)
activity and total anti-oxidant
capacity (TAC), c Pro-
oxidant-anti-oxidant balance
(PAB) and d Parameters of tissue
damage: malondialdehyde
(MDA) and advanced oxidation
protein products (AOPP) levels,
at the peak of EAE in the plasma
of female and male rats
administered with DMF (+DMF)
or vehicle (−DMF). Results are
from one of two similar
experiments each comprising six
rats/group. Data are presented as
mean ± S.E.M. Two-way
ANOVA showed significant
interaction between the effects of
treatment and sex for SOD
(F(1,20) = 7.257; p ≤ 0.05), TAC
(F(1,20) = 6.183; p ≤ 0.05), PAB
(F(1,20) = 7.929; p ≤ 0.05), and
AOPP (F(1,20) = 5.039; p ≤ 0.05).
*p ≤ 0.05; **p ≤ 0.01;
***p ≤ 0.001
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rats of both sexes, but this effect was more prominent inmales,
leading to the loss of the sexual dimorphism observed in con-
trol −DMF rats. This sexual diergism cannot be ascribed to sex
differences in either metabolism or pharmacokinetic profile of
DMF (European Medicines Agency 26 November 2013
EMA/800904/2013 Corr. 1 Committee for Medicinal
Products for Human Use (CHMP) Assessment report:
Tecfidera, http://www.ema.europa.eu/ema/index.jsp?curl=
pages/medicines/human/medicines/002601/human_med_
001657.jsp&mid=WC0b01ac058001d124). Thus, it may be
assumed that this phenomenon reflected sex differences in
the sensitivity of DMF targets. DMF is shown to exert
beneficial effects on EAE by affecting multiple cellular and
molecular targets [9, 12, 64, 65], so its influence on distinct
targets was systematically examined.
DMF Exerted more Pronounced
Immunomodulatory/Anti-inflammatory Effects in Male
Rats
In accordance with the previous studies [64, 65], we retrieved
fewer mononuclear cells, and CD4+ T lymphocytes among
them, from +DMF rats compared with sex-matched −DMF
animals, and revealed that the magnitude of this DMF effect
was greater in males, leading to the loss of sexual dimorphism
observed in controls. Although DMF is shown to induces
apoptosis in purified human T lymphocytes [43], we failed
to show any significant changes in the frequency of Annexin
V+ cells among CD4+ T lymphocytes from either female or
male SC. Given that the frequency of apoptotic cells among T
cells from fresh SC mononuclear cell suspensions, differently
from that among purified T lymphocytes in culture, reflects
not only proapototic DMF action, but also efficacy of phago-
cytic cell to eliminate apoptotic cells, this apparent discrepan-
cy could be reconciled by our findings indicating that: (i) the
DMF-induced increase in the frequency of phagocyting anti-
inflammatory CD163+ cells within CD11b+CD45+TCRαβ-
myeloid cells, and (ii) this increase was more prominent in
males. Several findings strongly corroborate the notion indi-
cating that DMF augments the elimination of apoptotic cells
by increasing the frequency of phagocyting CD163+ cells.
Firstly, it is shown that CD163+ microglial cells/
macrophages accumulating in acute active MS lesions are
myelin basic protein positive, i.e., the cells that ingested tissue
debris [54]. Secondly, in vitro incubation of LPS-stimulated
macrophage cell line RAW264.7 with myelin turned these
cells from inflammatory into phagocyting cells exhibiting
CD163+ anti-inflammatory phenotype [54]. Furthermore,
DMF induced changes in the frequency of cells bearing
CD83, the molecule strongly upregulated in phagocyting cells
by apoptotic cell-derived membrane vesicles [55] and its sur-
face density on these cells showed the same pattern as that in
CD163+ cell frequency. Moreover, given that CD163+
myeloid cells, which are shown to be crucial in restricting
neuroinflammation in acute EAE model, express Arg-1 [59],
the augmented Arg-1 expression in SC from +DMF rats, be-
ing particularly pronounced in males, is also fully consistent
with the DMF-induced alterations in the frequency of
CD163+ myeloid cells. The opposite influence of DMF on
the SC expression of Arg-1 and iNOS supports the previous
findings [60]. The additional support for the herein reported
DMF-induced alterations in the frequency of CD163+ mye-
loid cells comes from our findings showing that DMF upreg-
ulated the expression of Nrf2 and HO-1, in a sex-specific way.
Namely, it has been recently shown that: (i) DMF exerts fa-
vorable clinical effects in rat experimental autoimmune neuri-
tis model and mouse acute EAE model by increasing the
number of anti-inflammatory macrophages in the spleen and
sciatic nerves, respectively [12, 51] and (ii) these DMF effects
are, at least partly, related to the mobilization of anti-
inflammatory Nrf2/HO-1 axis and upregulation of HO-1 level
[12, 51]. To corroborate sex differences in the magnitude of
DMF effects on Nrf2/HO-1 axis are data showing sex differ-
ences in basal and induced Nrf2/HO-1 pathway activity and
HO-1 levels in neural and extraneural tissues [66–68].
Additionally, it should be pointed out that the diminished in-
filtration of SC with CD4+ T lymphocytes in the response to
DMF could be ascribed to their impaired migration [65,
69–71], reflecting inhibitory effect of DMF on NF-κB-
dependent transcription of genes encoding chemokines and
adhesion molecules [14, 15]. In this context, sexual dimor-
phism in DMF influence on the number of CD4+ T lympho-
cytes infiltrating SC may be related to (i) sex-based differ-
ences in basal and stimulated NF-κB expression and activity
[72, 73] and (ii) herein reported sex-specific influence of DMF
on Nrf2 expression, as DMF-induced Nrf2 signaling pathway
activity leads to inhibition of NF-kB activation [9, 17, 18,
74] and vice versa. Finally, considering that the dimin-
ished CD134 surface density on CD4+ T lymphocytes
limits their clonal expansion and survival [75], sex-
specific (i.e., particularly pronounced in males) decrease
in the CD134 surface density on CD134+CD4+ T lym-
phocytes is also consistent with our assumption that
DMF-induced sex-specific changes in the frequency of
phagocyting CD163+ cells mask its proapoptotic effect
on CD4+ T lymphocytes. The sex-specific DMF-induced
effect on CD4+ T lymphocyte reactivation (substantiated
in more prominent the decrease in not only CD134 sur-
face expression, but also in the frequency CD134+ lym-
phocytes in males) is consistent with data indicating that
in vitro DMF diminishes antigen-specific proliferation of
splenocytes obtained from a rat model of experimental
autoimmune neuritis [51]. The sex-specific diminishing
effect of DMF on CD4+ T lymphocyte proliferation could
be linked with the sexually dimorphic DMF upregulation
of CD83 surface density on myeloid CD11b+CD45+
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TCRαβ−cells, as CD83 is suggested to play an important
inhibitory role during interactions between antigen pre-
senting and T cells [76–79]. More specifically, CD83 re-
leased from activated non-lymphoid cells (through shed-
ding of cell surface-associated CD83), and in the soluble
form, strongly down modulates the antigen presenting
cell-mediated T lymphocyte stimulation [77–79]. To add
an extra weight to our assumption is the study describing
effects of the treatment with soluble CD83 on neuroin-
flammation in a murine EAE model (also CD4+ T cell-
mediated disease model for the early inflammatory stage
of MS) [80]. The study showed that the administration of
soluble CD83 during the initial phase of EAE (the immu-
nological onset of the disease), or at a later period, which
spans the onset of the first clinical symptoms, clearly re-
duced the paralysis [80]. In the same line are recently
obtained data indicating that highly upregulated CD83
expression on dendritic cell surface, through CD83
homotypic interactions, leads to downregulation of in-
flammation and promotion of mucosal homeostasis in an
experimental colitis model [81].
Apart from diminishing the number of CD4+ T lympho-
cytes infiltrating SC, in agreement with the findings from
mouse EAE model and MS [12, 82], DMF reduced the num-
ber of IL-17+ T lymphocytes infiltrating SC, and the frequen-
cy of IFN-γ+GM-CSF+ cells, which are shown to comprise
highly pathogenic in EAEmodels. These effects of DMFwere
also more prominent in males, leading to the loss of the sexual
dimorphism observed in controls. To support the latter finding
was the more pronounced DMF-related decrease in the fre-
quency of CD11b-expressing (CD11b+) T lymphocytes in
males (Supplementary Fig. 1). In EAE animals, CD11b+ T
cells isolated from SC are suggested to correspond to patho-
genic GM-CSF-producing T lymphocytes [53]. The previous
findings could be, at least partly, related to the sex-specific
DMF-induced changes in the SC myeloid cell M2 polariza-
tion, and consequent changes in the expression of cytokines
(IL-1β and IL-6) driving differentiation of highly pathogenic
IL-17+ T lymphocytes [12, 82].
DMF was Efficiently Reduced Oxidative Stress in Male
Rats Immunized for EAE
In accordance with the sexually dimorphic immunoregulatory/
anti-inflammatory effects of DMF observed at lymphocyte and
myeloid cell population level, sexually dimorphic magnitude of
the decrease in SC levels of both NO and O2
• − was found in
+DMF rats compared with controls. However, considering that
(i) NF-κB-targeted genes play a major role in the regulation of
ROS and RNS generation at the level of single cell [83, 84] and
(ii) DMF inhibits NF-kB-dependent gene transcription [14, 15],
in a sexually dimorphic manner [72, 73], it may be assumed
that the effects of DMF on the generation of damaging pro-
oxidants also reflected DMF-induced changes at the single-
cell level. Additionally, DMF enhanced the activity of cell de-
fense mechanisms, in a sex-specific manner. Namely, it en-
hanced SOD activity in rats of both sexes, but to a greater
extent in males, abrogating the sexual dimorphism regis-
tered in −DMF rats. This most likely reflected sexually
dimorphic influence on Nrf2 expression [85]. Furthermore,
in accordance with findings indicating that prolonged DMF
treatment leads to upregulation of anti-oxidant responses, in-
cluding GSH response [63], we found elevated GSH levels in
SC of +DMF rats compared with sex-matched −DMF once.
However, differently from SOD response, this response was
not sexually dimorphic. The data indicating that fumaric acid
esters may modulate cellular GSH through Nrf2-independent
mechanisms [86], may offer a plausible explanation for the
previous findings. The diminished pro-oxidant generation in
SC accompanied by enhanced neuroprotective mechanisms in
response to DMF led to diminished MDA in +DMF rats of
both sexes and AOPP levels in male +DMF rats in respect to
their −DMF counterparts. This is consistent with data indicat-
ing sexual dimorphism in mechanisms playing protective/
reparatory role in SC tissue damage [87].
Finally, consistent with our previous study [7], the changes
in SC redox status registered in +DMF rats were followed by
alterations in the parameters of plasma redox status. It has
been previously shown that plasma AOPP level may be used
as a simple plasma marker to assess EAE activity, predict the
severity of disease course, and perhaps response to therapy
[7]. Indeed, in male rats, DMF diminished plasmaAOPP level
and abolished sexual dimorphism observed in −DMF rats
characterized by the greater AOPP value in males exhibiting
more severe neurologic deficit. Additionally, a high correla-
tion (0.762; p ≤ 0.001) betweenMDA levels in SC and plasma
PAB levels was observed. This is also consistent with our
previous study showing that PAB may be used as a parameter
indicating the degree of SC oxidative damage [7].
Conclusions
DMF significantly attenuated EAE severity in rats of both
sexes, leading to loss of the sexual dimorphism observed in
control animals. The sex-specific influence of DMF on clini-
cal EAE underpinned sex-based differences in DMF efficacy
to induce anti-inflammatory phagocyting myeloid cells with,
most likely, high expression of regulatory CD83 molecule
(Fig. 8). This phenomenon most likely contributed the height-
ened sensitivity of genes encoding Nrf2/HO-1 expression to
DMF in males. To support this notion are data indicating (i)
sex bias in basal and stimulated Nrf2 expression in neural and
non-neural tissues [66–68] and (ii) sex differences in the re-
sponsiveness of some other genes to induction by different,
including anti-oxidant, agents [88, 89]. Consistent with the
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changes at myeloid cell level, the greater efficacy of DMF in
impairing CD4+ T cell reactivation and possibly survival, and
differentiation of highly pathogenic IFN-γ+GM-CSF+IL-17+
T lymphocytes was found in males (Fig. 8). These diergisms
at cell population level coupled with sex bias in DMF efficacy
to enhance anti-oxidant defense through its action on Nrf2-
mediated expression of anti-oxidant genes contributed to low-
er SC oxidative stress in males (Fig. 8). To corroborate this
notion is sex bias in the neuroprotective effects of some other
anti-oxidants in rat model of hypoxia-ischemia-induced brain
injury [90]. Additionally, the study supported our previous
findings indicating that AOPP level may be used as a plasma
marker to assess EAE activity and predict the response to
therapy [7]. Overall, these findings, apart from fundamental
importance for understanding sex bias in mechanisms deter-
mining the severity of neuroinflammation in EAE, and possi-
bly MS, seem to be encouraging for sex/gender-based clinical
studies aimed to optimize immunomodulatory/anti-oxidant
therapy of MS taking into account patient’s sex. The latter is
important given that, sex-specific differences for some clinical
outcomes in patients with MS who received the disease mod-
ifying therapies, including DMF, have occasionally been ob-
served, but not systematically statistically analyzed to draw
relevant conclusions [25].
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